Cargando…

Function matters: Coronavirus cross-binding antibodies do not cross-neutralize

BACKGROUND: During the current pandemic, the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) neutralization capacity of the immunoglobulin (IG) supply has changed from undetectable for lots manufactured from plasma collected before the pandemic, to now highly potent. OBJECTIVE: As antib...

Descripción completa

Detalles Bibliográficos
Autores principales:	Farcet, Maria R., Schwaiger, Julia, Karbiener, Michael, Kreil, Thomas R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9378960/ https://www.ncbi.nlm.nih.gov/pubmed/35983096 http://dx.doi.org/10.3389/fmed.2022.924426

Ejemplares similares

Omicron Severe Acute Respiratory Syndrome Coronavirus 2 Neutralization by Immunoglobulin Preparations Manufactured From Plasma Collected in the United States and Europe( )
por: Farcet, Maria R, et al.
Publicado: (2022)

Rapidly Increasing Severe Acute Respiratory Syndrome Coronavirus 2 Neutralization by Intravenous Immunoglobulins Produced From Plasma Collected During the 2020 Pandemic( )
por: Farcet, Maria R, et al.
Publicado: (2021)

No SARS-CoV-2 Neutralization by Intravenous Immunoglobulins Produced From Plasma Collected Before the 2020 Pandemic
por: Schwaiger, Julia, et al.
Publicado: (2020)

Feasibility of identifying plasma donors with high measles neutralizing antibody concentrations for the use of producing a measles hyperimmune globulin for postexposure prophylaxis
por: Lackner, Cornelia, et al.
Publicado: (2022)

Plasma from post-COVID-19 and COVID-19-Vaccinated Donors Results in Highly Potent SARS-CoV-2 Neutralization by Intravenous Immunoglobulins
por: Karbiener, Michael, et al.
Publicado: (2021)

Calibrated comparison of SARS-CoV-2 neutralizing antibody levels in response to protein-, mRNA-, and vector-based COVID-19 vaccines
por: Karbiener, Michael, et al.
Publicado: (2022)

Detergent-Mediated Virus Inactivation in Biotechnological Matrices: More than Just CMC
por: Farcet, Jean-Baptiste, et al.
Publicado: (2023)

Synthesis of “Nereid,” a new phenol‐free detergent to replace Triton X‐100 in virus inactivation
por: Farcet, Jean‐Baptiste, et al.
Publicado: (2020)

Longitudinal analysis of SARS‐CoV‐2 antibodies in 8000 U.S. first‐time convalescent plasma donations
por: Karbiener, Michael, et al.
Publicado: (2021)

SARS-CoV-2-Specific Antibody (Ab) Levels and the Kinetic of Ab Decline Determine Ab Persistence Over 1 Year
por: Garner-Spitzer, Erika, et al.
Publicado: (2022)

Epitope mapping of severe acute respiratory syndrome coronavirus 2 neutralizing receptor binding domain-specific monoclonal antibodies
por: Maghsood, Faezeh, et al.
Publicado: (2022)

Orthopox viruses and the safety margins of solvent‐detergent treated plasma‐derived medicinal products
por: Kindermann, Johanna, et al.
Publicado: (2022)

Coronavirus Pseudotypes for All Circulating Human Coronaviruses for Quantification of Cross-Neutralizing Antibody Responses
por: Sampson, Alexander Thomas, et al.
Publicado: (2021)

Cross-neutralization of SARS coronavirus-specific antibodies against bat SARS-like coronaviruses
por: Zeng, Lei-Ping, et al.
Publicado: (2017)

Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects
por: Jennewein, Madeleine F., et al.
Publicado: (2021)

Neutralizing Antibodies against SARS-CoV-2 and HLA Class I and II Polymorphism
por: Weidner, Lisa, et al.
Publicado: (2021)

Antibodies induced by receptor-binding domain in spike protein of SARS-CoV do not cross-neutralize the novel human coronavirus hCoV-EMC
por: Du, Lanying, et al.
Publicado: (2013)

Case Report: Circulating Anti-SARS-CoV-2 Antibodies Do Not Cross-React With Pemphigus or Pemphigoid Autoantigens
por: Kasperkiewicz, Michael, et al.
Publicado: (2021)

Antibody‐enhanced hepatitis E virus nanofiltration during the manufacture of human immunoglobulin
por: Kapsch, Anna‐Maria, et al.
Publicado: (2020)

Asprosin-neutralizing antibodies as a treatment for metabolic syndrome
por: Mishra, Ila, et al.
Publicado: (2021)

Quantification of SARS-CoV-2 antibodies with eight commercially available immunoassays
por: Weidner, Lisa, et al.
Publicado: (2020)

Relative Ratios of Human Seasonal Coronavirus Antibodies Predict the Efficiency of Cross-Neutralization of SARS-CoV-2 Spike Binding to ACE2
por: Galipeau, Yannick, et al.
Publicado: (2021)

Neutralising SARS-CoV-2 RBD-specific antibodies persist for at least six months independently of symptoms in adults
por: Wagner, Angelika, et al.
Publicado: (2021)

SARS-CoV-2 and the safety margins of cell-based biological medicinal products
por: Modrof, Jens, et al.
Publicado: (2020)

Antibodies against Marinobacter algicola and Salmonella typhimurium Flagellins Do Not Cross-Neutralize TLR5 Activation
por: Terron-Exposito, Raul, et al.
Publicado: (2012)

COVID-19 reinfection in the presence of neutralizing antibodies
por: Zhang, Ju, et al.
Publicado: (2021)

Stabilization of a Broadly Neutralizing Anti-Chikungunya Virus Single Domain Antibody
por: Liu, Jinny L., et al.
Publicado: (2021)

Binding and neutralizing antibody responses to SARS-CoV-2 in very young children exceed those in adults
por: Karron, Ruth A., et al.
Publicado: (2022)

Cross-reactive broadly neutralizing antibodies: timing is everything
por: Euler, Zelda, et al.
Publicado: (2012)

Broadly neutralizing antibodies target the coronavirus fusion peptide
por: Dacon, Cherrelle, et al.
Publicado: (2022)

Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions
por: Shiakolas, Andrea R., et al.
Publicado: (2021)

Broadly neutralizing antibodies target the coronavirus fusion peptide
por: Dacon, Cherrelle, et al.
Publicado: (2022)

Characterization of 100 sequential SARS‐CoV‐2 convalescent plasma donations
por: Jungbauer, Christof, et al.
Publicado: (2020)

Cross-Neutralizing and Protective Human Antibody Specificities to Poxvirus Infections
por: Gilchuk, Iuliia, et al.
Publicado: (2016)

Structure of Severe Acute Respiratory Syndrome Coronavirus Receptor-binding Domain Complexed with Neutralizing Antibody
por: Prabakaran, Ponraj, et al.
Publicado: (2006)

Coronaviruses pandemics: Can neutralizing antibodies help?
por: Tong, Phuoc-Bao-Viet, et al.
Publicado: (2020)

Development of Coronavirus Treatments Using Neutralizing Antibodies
por: Fouladirad, Saman, et al.
Publicado: (2021)

Host-directed therapy with 2-deoxy-D-glucose inhibits human rhinoviruses, endemic coronaviruses, and SARS-CoV-2
por: Wali, Laxmikant, et al.
Publicado: (2022)

Cross-neutralizing antibodies bind a SARS-CoV-2 cryptic site and resist circulating variants
por: Li, Tingting, et al.
Publicado: (2021)

Inducing Cross-Clade Neutralizing Antibodies against HIV-1 by Immunofocusing
por: Humbert, Michael, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_67t5ave9snsnsnaqq9snbp42b0